The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...

Can supplementing with vitamins and minerals protect your eye health? Learn more about the role of nutrients in age-related ...

AI has quietly revolutionized the field of ophthalmology.While the concept of AI may evoke futuristic images of robots and ...

Sienna Eye Care will provide personalized solutions for eye conditions such as dry eyes, glaucoma, macular degeneration and diabetic retinopathy. It also will provide pediatric evaluations and myopia ...

Background: This study was performed to assess the prevalence of dry eye syndrome and diabetic retinopathy (DR) in type 2 diabetic patients and their contributing factors. Methods: 199 type 2 ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.

Artificial Intelligence (AI) is revolutionising predictive healthcare, offering early disease detection, personalised ...

Goldman Sachs made a significant adjustment to its stance on Regenxbio Inc . (NASDAQ:RGNX), downgrading the stock from "Buy" to "Neutral" and reducing the price target dramatically to $14.00 from the ...